Vitamin K supplementation reduces serum concentrations of under-γ-carboxylated osteocalcin in healthy young and elderly adults
Open Access
- 1 December 2000
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 72 (6), 1523-1528
- https://doi.org/10.1093/ajcn/72.6.1523
Abstract
Background: Subclinical vitamin K insufficiency, manifested by under-γ-carboxylation of the bone matrix protein osteocalcin, may be common. Objective: Our objective was to delineate the prevalence of submaximal γ-carboxylation as assessed by response to phylloquinone supplementation and to evaluate the effect of this intervention on skeletal turnover in healthy North American adults. Design: Healthy subjects (n = 219), approximately equally distributed by sex and age (18–30 y and ≥65 y), received daily phylloquinone (1000 μg) or placebo for 2 wk. Serum undercarboxylated osteocalcin (ucOC) and total osteocalcin, N-telopeptides of type I collagen (NTx), bone-specific alkaline phosphatase (BSAP), and phylloquinone concentrations were measured at baseline and after weeks 1 and 2. Results: At baseline, the mean serum phylloquinone concentration was lower in the young than in the old group; there was no effect of sex. Concomitantly, baseline %ucOC was highest in the young and lowest in the old men (P < 0.0001) but did not differ significantly by age in women. After supplementation, serum phylloquinone concentration increased ≈10-fold (P < 0.0001) at week 1 (from 0.93 ± 0.08 to 8.86 ± 0.70 nmol/L, x̄ ± SEM); this was sustained through week 2. Among all supplemented groups, mean %ucOC decreased from 7.6% to 3.4% without significant differences by age or sex; 102 of 112 subjects had a >1% decrease. Phylloquinone supplementation reduced serum osteocalcin but did not alter NTx or BSAP concentration. Conclusions: Usual dietary practices in this population did not provide adequate vitamin K for maximal osteocalcin carboxylation. Phylloquinone supplementation reduced serum osteocalcin concentration but did not alter other markers of serum bone turnover.Keywords
This publication has 33 references indexed in Scilit:
- Long-term Oral Anticoagulation Reduces Bone Mass in Patients with Previous Hemispheric Infarction and Nonrheumatic Atrial FibrillationStroke, 1997
- Changes in serum osteocalcin, plasma phylloquinone, and urinary gamma-carboxyglutamic acid in response to altered intakes of dietary phylloquinone in human subjectsThe American Journal of Clinical Nutrition, 1997
- Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: A three year follow-up studyBone, 1996
- Comparison of biochemical indexes for assessing vitamin K nutritional status in a healthy adult populationThe American Journal of Clinical Nutrition, 1996
- Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly womenJournal of Bone and Mineral Research, 1994
- Vitamin K-induced changes in markers for osteoblast activity and urinary calcium lossCalcified Tissue International, 1993
- Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.Journal of Clinical Investigation, 1993
- Decreased peripheral bone mineral content in patients under anticoagulant therapy with phenprocoumonEuropean Heart Journal, 1991
- Reduced Axial Bone Mineral Content in Patients Taking an Oral AnticoagulantSouthern Medical Journal, 1990
- The Effect of Vitamin K Supplementation on Circulating Osteocalcin (Bone Gla Protein) and Urinary Calcium ExcretionAnnals of Internal Medicine, 1989